DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs

NCT04811443 · clinicaltrials.gov ↗

UNKNOWN

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Patients With Solid Tumours Who Receive Myelosupressive Therapy

Interventions

DRUG: Empegfilgrastim

Sponsor

Biocad